Loading organizations...
§ Private Profile · Kyoto-shi, Kyoto, Japan
Biotechnology and regenerative medicine company developing iPS cell products for severe heart failure patients, focused on heart tissue.
iHeart Japan, based in Kyoto, Japan, develops regenerative medical products utilizing iPS cell technology to treat severe heart failure patients. The company specializes in creating three-dimensional heart tissue from human iPS cells for implantation in patients lacking heart transplant options, alongside offering research tools and contract services. To date, iHeart Japan has raised a total of $16.29 million in funding, reaching the Series C stage. Key investors include the Japan Agency for Medical Research and Development (AMED), New Energy and Industrial Technology Development Organization (NEDO), and SBI Investment. Founder and president Kenji Kakuta, recognized as a Forbes Japan "superstar entrepreneur" in 2024, established the company in 2013. The firm focuses on biotechnology and regenerative medicine, severe heart failure patients and medical research sectors.
iHeart Japan has raised $5.4M across 1 funding round.
iHeart Japan has raised $5.4M in total across 1 funding round.
iHeart Japan has raised $5.4M across 1 funding round. Most recently, it raised $5.4M Series D in September 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2025 | $5.4M Series D | Mitsui Sumitomo Insurance Venture Capital | — | Announced |
iHeart Japan has raised $5.4M in total across 1 funding round.
iHeart Japan's investors include Mitsui Sumitomo Insurance Venture Capital.